![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
PEGINTERFERON LAMBDA-1a(LAMBDA) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGINTERFERON ALFA-2a(ALFA-2a) IN PATIENTS WITH CHRONIC HCV INFECTION (G1/2/3/4): EMERGE PHASE 2bTHROUGH WEEK 12RESULTS
|
|
|
Reported by Jules Levin <
The 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2012), Taipei International ConventionCenter, February 16-19, 2012 <
RODRIGUEZ-TORRES M,1ISHAK L,2FONTANA D,2XU D,3GRAY T,2HORGA A,3HILLSON J,2ZEUZEM S,4LOPEZ-TALAVERA JC,3FOR THE EMERGE STUDY GROUP1FUNDACION DE INVESTIGACION, SAN JUAN, PUERTO RICO; 2ZYMOGENETICS/BMS, SEATTLE, WA, USA; 3BRISTOL-MYERS SQUIBB, WALLINGFORD, CT, USA; 4KLINIKUM DER JOHANN-WOLFGANG GOETHE-UNIVERSITAT, FRANKFURT/MAIN, GERMANY
![APASL1.gif](../images/022712/022712-2/APASL1.gif)
![APASL2.gif](../images/022712/022712-2/APASL2.gif)
![APASL3.gif](../images/022712/022712-2/APASL3.gif)
![APASL4.gif](../images/022712/022712-2/APASL4.gif)
![APASL5.gif](../images/022712/022712-2/APASL5.gif)
![APASL6.gif](../images/022712/022712-2/APASL6.gif)
![APASL7.gif](../images/022712/022712-2/APASL7.gif)
![APASL8.gif](../images/022712/022712-2/APASL8.gif)
![APASL9.gif](../images/022712/022712-2/APASL9.gif)
![APASL10.gif](../images/022712/022712-2/APASL10.gif)
![APASL11.gif](../images/022712/022712-2/APASL11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|